SpecGx LLC has received FDA approval for ANDA 219395, signaling an imminent opportunity for the company to enter the market with the companion diagnostic product. This regulatory milestone positions SpecGx to capitalize on the growing demand for precision medicine diagnostics amid anticipated demand for the associated therapeutic.